Protalix Biother Stock Price, News & Analysis

Protalix BioTherapeutics (NYSE American:PLX), a biopharmaceutical company specializing in plant cell-based protein expression systems, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.

CEO Dror Bashan will deliver a presentation on Monday, September 8, 2025, at 3:30 PM EDT in the Holmes II Room at the Lotte New York Palace Hotel. The management team will also engage in one-on-one meetings with registered investors throughout the conference.

Protalix BioTherapeutics (NYSE American: PLX) reported strong Q2 2025 financial results, with revenues from goods increasing 16% to $15.4 million compared to Q2 2024. The company achieved net income of $164,000 versus a net loss of $2.2 million in the same period last year. The growth was primarily driven by increased sales of Elfabrio® to Chiesi in the $2.3 billion global Fabry disease market.

Key developments include the appointment of Gilad Mamlok as new CFO effective August 24, 2025, replacing Eyal Rubin, and the company's addition to the Russell 3000® and Russell 2000® Indexes. Protalix plans to initiate a Phase 2 trial for PRX-115, their gout treatment candidate, in Q4 2025. The company ended the quarter with $33.4 million in cash and cash equivalents.

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in ProCellEx® plant cell-based protein expression system, will release its Q2 2025 financial results on August 14, 2025. The company will host a conference call and webcast at 8:30 a.m. EDT to discuss financial results and provide corporate and regulatory updates.

The conference call will be accessible via multiple channels, including toll-free numbers for US and Israeli participants, and will feature a convenient Call me™ feature. A webcast replay will be available for two weeks following the presentation on the company's investor relations website.

Protalix BioTherapeutics (NYSE American: PLX) has appointed Gilad Mamlok as its new Senior Vice President and Chief Financial Officer, effective August 24, 2025. Mamlok brings three decades of experience in healthcare and technology companies, with expertise in capital markets, M&A, and business development.

Mamlok will succeed Eyal Rubin, who will remain available to the company until October 2025 to ensure a smooth transition. Mamlok's recent experience includes CFO positions at TytoCare Ltd. and Sol-Gel Technologies Ltd., where he led significant capital markets transactions and licensing deals. He previously worked at Given Imaging, which was acquired by Covidien in 2014.

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in plant cell-based protein expression systems, has announced its addition to the Russell 3000® and Russell 2000® Indexes effective June 27, 2025. This inclusion is part of the 2025 Russell indexes annual reconstitution.

The Russell indexes, which benchmark approximately $10.6 trillion in assets, are widely utilized by investment managers and institutional investors. Membership in these indexes is determined by market capitalization rankings and style attributes, with the Russell 3000® Index capturing the 4,000 largest US stocks as of April 30.

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system, will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference. The event will take place on Tuesday, May 20, 2025, at the Nasdaq headquarters in New York City.

The company's Sr. Vice President and CFO, Eyal Rubin, will deliver a presentation and be available for one-on-one meetings with investors. The presentation will be webcast live at 4:30 pm EDT and can be accessed through the company's investor relations website or via the provided webcast link.

Protalix BioTherapeutics (NYSE: PLX) reported Q1 2025 financial results, showing significant revenue growth. Revenue from goods increased 170% to $10.0 million compared to $3.7 million in Q1 2024, primarily driven by increased sales to Pfizer ($5.9 million increase). The company reported a net loss of $3.6 million ($0.05 per share), improved from $4.6 million loss in Q1 2024. Research and development expenses increased 21% to $3.5 million, while selling and administrative expenses decreased 16% to $2.6 million. Cash position stood at $34.7 million as of March 31, 2025. The company is advancing its PRX-115 gout treatment candidate, with plans to initiate a Phase II clinical trial in H2 2025 following successful completion of First-in-Human studies.

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based expression system, has scheduled its Q1 2025 financial results release and business update for May 9, 2025.

The company will host a conference call and webcast at 8:30 a.m. EDT to discuss financial results and provide updates on corporate and regulatory developments. The call will be accessible via toll-free numbers for domestic and Israeli callers, with international lines available. A replay will be available for two weeks through the company's investor relations website.

Protalix BioTherapeutics (NYSE American: PLX), a biopharmaceutical company specializing in recombinant therapeutic proteins using their proprietary ProCellEx® plant cell-based expression system, has announced their participation in the upcoming iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025.

The virtual conference is scheduled for March 25-26, 2025, featuring a two-day format with webcast presentations on the first day and one-on-one meetings between Protalix management and pre-qualified investors on the second day. The conference is organized by iAccess Alpha, which hosts virtual investor conferences for recommended companies.

Interested participants are advised to join the call 15 minutes early to complete necessary technical preparations. A recording of the presentation will remain accessible for at least six months through the Events Calendar in the Investors section of Protalix's website.